Skip to content

frontMIND — Tafasitamab + lenalidomide + R-CHOP, 1L high-risk DLBCL/HGBL

Abstract: LBA7000 · Session: Oral Abstract Session — Hematologic Malignancies: Lymphoma and Chronic Lymphocytic Leukemia, Sat May 30, 2026, 3:00–6:00 PM CT (4:00–7:00 PM ET) · Presenter: Georg Lenz, MD (University Hospital Münster, Germany) · Embargo: May 30, 2026

At a glance

  • Sponsor: Incyte
  • PI / presenter: Georg Lenz, MD (University Hospital Münster, Germany); co-authors incl. M. Trněný, J.M. Burke
  • NCT ID: NCT04824092
  • Phase: 3 (randomized, double-blind, placebo-controlled, global)
  • Design: Tafasitamab + lenalidomide + R-CHOP vs placebo + R-CHOP, 6 cycles, then tafa+len maintenance
  • N: 899 adults, age 18–80 (tafa-len-R-CHOP n=448; R-CHOP n=451)
  • Primary endpoint(s): Investigator-assessed PFS (ITT)
  • Comparator: R-CHOP + placebo
  • Indication: Newly diagnosed high-intermediate / high-risk DLBCL or high-grade B-cell lymphoma (HGBL); IPI 3–5, or aaIPI 2–3 if ≤60 yrs
  • Line: First-line (1L)

Headline result

At a median follow-up of 35.2 months (data cutoff Oct 20, 2025), frontMIND met its primary endpoint: investigator-assessed PFS favored tafasitamab + lenalidomide + R-CHOP over R-CHOP alone, with HR 0.75 (95% CI 0.59–0.96; P=.0194) — a 25% reduction in risk of progression or death. Median PFS was not reached in either arm; the absolute PFS benefit was 8.2% at 2 years (24-month PFS 71.1% vs 62.9%) and 6.6% at 3 years (36-month PFS 67.3% vs 60.7%). The benefit was deeper in the centrally confirmed DLBCL/HGBL subset (n=773; HR 0.68, 95% CI 0.52–0.88). The key secondary endpoint of event-free survival was also met (HR 0.79, 95% CI 0.64–0.97; P=.0260; 24-mo 65.0% vs 56.7%). Interim OS favored the triplet but did not reach significance (HR 0.85, 95% CI 0.63–1.14; P=.2703; 82 deaths [18.5%] vs 97 [21.7%]; 24-mo 84.1% vs 80.5%). CR/ORR were similar between arms. Safety: grade ≥3 TEAEs 86.7% vs 76.1%, most commonly anemia (22.8%), thrombocytopenia (13.1%), and neutropenia (12.4%), with no new safety signals; treatment discontinuation 5.2% vs 5.4%; R-CHOP dose intensity preserved in both arms.

Mechanism / class

Tafasitamab (Monjuvi/Minjuvi) is a humanized, Fc-engineered anti-CD19 monoclonal antibody, already FDA-approved with lenalidomide for relapsed/refractory DLBCL not eligible for transplant (L-MIND). frontMIND moves the CD19 antibody + immunomodulatory backbone into the first-line setting on top of standard R-CHOP.

Discussant takeaway

Discussant flagged that the magnitude of OS benefit remains immature and that more data are needed on how prior tafasitamab (anti-CD19) exposure interacts with subsequent CD19-directed CAR T-cell therapy at relapse. Trade-press coverage framed the triplet as a potential "new standard" for newly diagnosed high-risk DLBCL/HGBL, the first regimen in years to beat R-CHOP on PFS in this population.

Practice-changing?

Pending. First positive frontline phase 3 regimen to add to R-CHOP and improve PFS in high-risk DLBCL/HGBL in this design, and Incyte plans a 2026 sBLA filing for the 1L indication. But median PFS was not reached, OS is not yet significant, grade ≥3 toxicity is higher, and unresolved CAR-T sequencing questions temper immediate standard-of-care adoption; broad uptake likely awaits regulatory action and maturing survival data.

Sources

  • ASCO Meeting Library (LBA7000): https://meetings.asco.org/abstracts-presentations/
  • Incyte press release (BusinessWire, Jan 2026 topline): https://www.businesswire.com/news/home/20260105730167/en/Incyte-Announces-Positive-Topline-Results-from-Pivotal-Study-of-Tafasitamab-MonjuviMinjuvi-as-a-First-line-Treatment-for-Diffuse-Large-B-Cell-Lymphoma
  • Incyte press release (BusinessWire, Apr 21, 2026): https://www.businesswire.com/news/home/20260421480376/en/Incyte-Highlights-New-Phase-3-Tafasitamab-Data-at-the-2026-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting
  • OncLive: https://www.onclive.com/view/frontmind-results-tafasitamab-based-combo-yields-significant-pfs-benefit-over-r-chop-in-frontline-high-risk-dlbcl
  • CancerNetwork (BCL groups): https://www.cancernetwork.com/view/tafasitamab-combo-prolongs-progression-vs-r-chop-alone-in-bcl-groups
  • CancerNetwork (newly diagnosed): https://www.cancernetwork.com/view/frontline-tafasitamab-combo-improves-pfs-in-newly-diagnosed-dlbcl
  • AJMC: https://www.ajmc.com/view/frontmind-results-with-tafasitamab-improve-pfs-25-over-r-chop-for-high-risk-dlbcl
  • Targeted Oncology: https://www.targetedonc.com/view/tafasitamab-plus-lenalidomide-and-r-chop-cuts-progression-risk-in-high-risk-dlbcl
  • Cancer Therapy Advisor: https://www.cancertherapyadvisor.com/reports/tafasitamab-triplet-newly-diagnosed-dlbcl-hgbl/
  • StockTitan / Incyte topline: https://www.stocktitan.net/news/INCY/incyte-s-pivotal-front-mind-trial-showed-tafasitamab-monjuvi-minjuvi-65lktc7s9sc6.html